Belantamab mafodotin (GSK2857916) is an investigational antibody-drug conjugate comprising a humanised anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker. BCMA is a pathway proven to be crucial for myeloma cell growth and survival; it is universally detected in myeloma cell lines. It is currently in clinical development by GlaxoSmithKline (GSK) together with Seattle Genetics in patients with relapsed/refractory multiple myeloma and other advanced haematologic malignancies expressing BCMA.
STATUS
Actively recruiting
CURRENT ENROLMENT
44 patients
Recruitment updated as of September 2022
STUDY DESIGN
Prospective, multicentre, open label trial, phase II study
CORRELATIVE STUDIES
Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile
TRIAL PRINCIPAL INVESTIGATOR
Associate Professor Hang Quach
TIME FRAME
2020 – 2024
PARTICIPANTS
Patients with relapsed refractory multiple myeloma who have had 1 to 3 prior lines of treatment
SITE LOCATIONS
- Alfred Hospital, VIC
- Geelong Hospital (Barwon Health), VIC
- St Vincent's Hospital Melbourne, VIC
- Flinders Medical Centre, SA
- Royal Adelaide Hospital, SA
- St Vincent's Hospital Sydney, NSW
- Concord Hospital, NSW
- Calvary Mater Hospital, NSW
- Border Medical Oncology, NSW
- The Townsville Hospital, QLD
- Royal Brisbane and Women's Hospital, QLD